| Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC (NCT04193098) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Personalized DC Vaccine for Postoperative Cancer (NCT04147078) | Sichuan University | 2019-06-01 |
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC (NCT03987867) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer (NCT02480634) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2019-06-01 |
| Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT04632758) | Qilu Pharmaceutical Co., Ltd. | 2019-06-01 |
| APG-2449 in Patients With Advanced Solid Tumors (NCT03917043) | Ascentage Pharma Group Inc. | 2019-05-27 |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours (NCT03852823) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-05-23 |
| Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC (NCT05637580) | Guangdong Provincial People's Hospital | 2019-05-20 |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade (NCT03474497) | Megan Daly, MD | 2019-05-20 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
| Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer (NCT03958097) | The First Hospital of Jilin University | 2019-05-17 |
| Crizotinib in ALK Rearranged Non-small-cell Lung Cancer (NCT04317651) | Fondazione Ricerca Traslazionale | 2019-05-16 |
| NADIM II: Neo-Adjuvant Immunotherapy (NCT03838159) | Fundación GECP | 2019-05-15 |
| Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (NCT03836066) | Fundación GECP | 2019-05-15 |
| Effect of Two Different Preoperative Training Densities in Patients With Non-small-cell Lung Cancer Before Lung Resection Surgery (NCT03936764) | ADIR Association | 2019-05-07 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (NCT03645928) | Iovance Biotherapeutics, Inc. | 2019-05-07 |
| Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (NCT03976518) | Gruppo Oncologico Italiano di Ricerca Clinica | 2019-05-07 |
| A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03743064) | Helsinn Healthcare SA | 2019-05-06 |
| Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI (NCT03924050) | Shanghai Junshi Bioscience Co., Ltd. | 2019-05-06 |
| The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial (NCT03859349) | St. Joseph's Healthcare Hamilton | 2019-05-06 |
| CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility (NCT03986463) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-05-01 |
| Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer (NCT03166254) | Washington University School of Medicine | 2019-04-30 |
| Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer (NCT04213170) | Sun Yat-sen University | 2019-04-29 |
| M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (NCT03840902) | EMD Serono Research & Development Institute, Inc. | 2019-04-16 |
| Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy (NCT03951012) | Muhammad Furqan | 2019-04-15 |
| Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (NCT03927573) | AvenCell Europe GmbH | 2019-04-15 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| Multiplex Analysis of Circulating Tumor DNA (NCT03301961) | Peking University People's Hospital | 2019-04-11 |
| Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (NCT03647163) | Vyriad, Inc. | 2019-04-09 |
| MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (NCT03865511) | Nantes University Hospital | 2019-04-09 |
| CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). (NCT03848611) | AnewPharma | 2019-04-02 |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients (NCT03924466) | Universitair Ziekenhuis Brussel | 2019-04-01 |
| BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics (NCT04136470) | Ardigen | 2019-04-01 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (NCT03846310) | Arcus Biosciences, Inc. | 2019-04-01 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272) | Agenus Inc. | 2019-03-20 |
| A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (NCT03819387) | Nitto BioPharma, Inc. | 2019-03-18 |
| Recurrence Monitoring in NSCLC Using Circulating Tumor DNA (NCT03878537) | Scripps Translational Science Institute | 2019-03-14 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) (NCT03829332) | Merck Sharp & Dohme LLC | 2019-03-13 |
| Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies (NCT03877250) | Memorial Sloan Kettering Cancer Center | 2019-03-08 |
| Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients (NCT03874000) | Tianjin Medical University Cancer Institute and Hospital | 2019-03-08 |
| A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer (NCT04641754) | Qilu Pharmaceutical Co., Ltd. | 2019-03-07 |
| Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC (NCT03998085) | The First Hospital of Jilin University | 2019-03-05 |
| Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma (NCT03827070) | Center Trials & Treatment Europe | 2019-03-05 |
| A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03743051) | Helsinn Healthcare SA | 2019-03-05 |
| A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC (NCT03823807) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-03-01 |
| Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC (NCT03900117) | Sun Yat-sen University | 2019-03-01 |
| Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive (NCT03790397) | Fundación GECP | 2019-02-26 |
| Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB (NCT04197076) | Shanghai Chest Hospital | 2019-02-25 |
| Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon) (NCT04857970) | Centre Hospitalier Universitaire de Besancon | 2019-02-20 |
| A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer (NCT03903887) | Sun Yat-sen University | 2019-02-19 |
| Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer (NCT03574220) | Case Comprehensive Cancer Center | 2019-02-19 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| A Study of a Personalized Neoantigen Cancer Vaccine (NCT03639714) | Gritstone bio, Inc. | 2019-02-13 |
| Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study (NCT03576937) | University Health Network, Toronto | 2019-02-12 |
| A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (NCT03782207) | Hoffmann-La Roche | 2019-02-07 |
| A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer (NCT03807778) | Takeda | 2019-02-04 |
| Dose Individualization of Pemetrexed - IMPROVE-I (NCT03656549) | Radboud University Medical Center | 2019-02-01 |
| A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients (NCT03849768) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-02-01 |
| Dose Individualization of Pemetrexed - IMPROVE-III (NCT03655834) | Radboud University Medical Center | 2019-02-01 |
| Dose Individualization of Pemetrexed - IMPROVE-II (NCT03655821) | Radboud University Medical Center | 2019-02-01 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (NCT03611738) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-01 |
| Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer (NCT03840408) | Shanghai 10th People's Hospital | 2019-01-31 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer (NCT03801304) | University Hospital, Brest | 2019-01-24 |
| Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (NCT03808480) | National Cancer Center, Korea | 2019-01-23 |
| Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance (NCT03833934) | Addario Lung Cancer Medical Institute | 2019-01-23 |
| Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study (NCT04069663) | University Hospital, Grenoble | 2019-01-22 |
| Safety and Efficacy of Lorbrena (NCT03844464) | Pfizer | 2019-01-21 |
| Study of NEO-201 in Solid Tumors Expansion Cohorts (NCT03476681) | Precision Biologics, Inc | 2019-01-18 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (NCT03808337) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (NCT03735290) | Mendus | 2019-01-14 |
| Molecular Profiling Project (NCT04025515) | National Cancer Centre, Singapore | 2019-01-11 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors (NCT03637803) | 4D pharma plc | 2019-01-10 |
| A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer (NCT03258788) | The Christie NHS Foundation Trust | 2019-01-03 |
| Lung Heart Rate Variability (NCT03674450) | Abramson Cancer Center at Penn Medicine | 2019-01-02 |
| Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer (NCT04144582) | Yongchang Zhang | 2019-01-01 |
| Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (NCT03798743) | Hunan Province Tumor Hospital | 2019-01-01 |
| Lindera Obtusiloba for Non-small Cell Lung Cancer (NCT04348149) | Jun-Yong Choi | 2018-12-28 |
| A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03735121) | Hoffmann-La Roche | 2018-12-27 |
| Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (NCT03726736) | Yong Fang | 2018-12-21 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (NCT03631199) | Novartis Pharmaceuticals | 2018-12-21 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Continued Access to RXDX-105 (NCT03784378) | Memorial Sloan Kettering Cancer Center | 2018-12-14 |
| A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (NCT03797391) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2018-12-13 |
| A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer (NCT03789604) | CStone Pharmaceuticals | 2018-12-13 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (NCT03800134) | AstraZeneca | 2018-12-06 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (NCT03736837) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-01 |
| The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) (NCT03811054) | Beijing Chest Hospital | 2018-12-01 |
| Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients (NCT02696525) | Peking University People's Hospital | 2018-12-01 |
| NGS Combined With RNAseq on Tumor Immune Escape in NSCLC (NCT03764917) | Shanghai Pulmonary Hospital, Shanghai, China | 2018-12-01 |
| McMaster Catheterization for Thoracoscopic Surgery Study (NCT02640326) | McMaster University | 2018-12-01 |
| Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation (NCT03754530) | Betta Pharmaceuticals Co., Ltd. | 2018-12-01 |
| Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (NCT03750916) | Qilu Hospital of Shandong University | 2018-11-30 |